A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110904 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Huantong Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Dis…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, CD5 Antigens. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Beijing Talents Fund, Beijing Municipal Excellent Talents Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor T cell (CAR-T) therapies show considerable clinical efficacy in patients with B cell malignancies, but their efficacy is limited in patients with T cell acute lymphoblastic leukemia (T-ALL). CD5 is expressed on ∼85 % of malignant T cells, and CD5-targeting CAR-T cells can exhibit potent antitumor activity against T-ALL. However, optimization of CAR costimulatory endo-, hinge, and transmembrane domains could further increase their expansion and persistence, thereby enhancing their efficacy following exposure to tumor cells. Here we designed CD5-specific CARs with different molecular structures to generate CAR-T cells and investigated their anti-tumor efficacy in vitro and in vivo. CD5 CARs with a 4-1BB costimulatory domain (BB.z) or a CD28 costimulatory domain (28.z) exhibited specific cytotoxicity against CD5+ malignant cells in vitro. However, both failed to prolong the survival of T-ALL xenograft mice. Subsequently, we substituted the 28.z CAR hinge region with CH2CH3, which enhanced the ability of CH2CH3-CD5 CAR-T cells to specifically eradicate T-ALL cells in vitro and in vivo. Furthermore, patient-derived CH2CH3-CD5 CAR-T cells were generated which showed a marked killing effect of CD5-positive acute T-ALL cells in vitro. The anti-tumor activity of CD5 CAR-T cells with a CD28 co-stimulation domain and CH2CH3 hinge region was superior to those with BB.z and 28.z domains. These preclinical data provided new insights into the factors dictating efficacy in T-ALL treatment with CAR-T cells and hold promise for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, and Key Laboratory of Neurodegenerative Diseases, Ministry of E…
Förderung
- Beijing Talents Fund
- Beijing Municipal Excellent Talents Foundation
- National Natural Science Foundation of China
- Beijing Municipal Health Commission
- Changshu Institute of Technology
- Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan
Zitieren
APA
Wu, H., Yu, Y., Zhao, Y., Liu, W., Liu, Z., Zhang, G., & Chen, Z. (2023). A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110904
Vancouver
Wu H, Yu Y, Zhao Y, Liu W, Liu Z, Zhang G, et al. A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110904
BibTeX
@article{Wu2023,
author = {Wu, Huantong and Yu, Yajie and Zhao, Yu and Liu, Weihua and Liu, Zhongfeng and Zhang, Guangji and Chen, Zhiguo},
title = {A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110904}
}
EUVIMED